Correlates and long-term outcomes of angiographically proven stent thrombosis with sirolimus- and paclitaxel-eluting stents

被引:532
|
作者
Kuchulakanti, PK [1 ]
Chu, WW [1 ]
Torguson, R [1 ]
Ohlmann, P [1 ]
Rha, SW [1 ]
Clavijo, LC [1 ]
Kim, SW [1 ]
Bui, A [1 ]
Gevorkian, N [1 ]
Xue, ZY [1 ]
Smith, K [1 ]
Fournadjieva, J [1 ]
Suddath, WO [1 ]
Satler, LF [1 ]
Pichard, AD [1 ]
Kent, KM [1 ]
Waksman, R [1 ]
机构
[1] Washington Hosp Ctr, Dept Med, Div Cardiol, Washington, DC 20010 USA
关键词
angioplasty; clopidogrel; stents; thrombosis;
D O I
10.1161/CIRCULATIONAHA.105.600155
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background - Stent thrombosis (ST) is a serious complication of drug-eluting stent ( DES) implantation regardless of the timing ( acute, subacute, or late). The correlates of ST with DES are not yet completely elucidated. Methods and Results - From a total cohort of 2974 consecutive patients treated with DES since April 2003, we identified 38 patients who presented with angiographic evidence of ST (1.27%). The ST occurred acutely in 5 patients, subacutely ( <= 30 days) in 25 patients, and late ( > 30 days) in 8 patients. The clinical, angiographic, and procedural variables of these patients were compared with the remaining 2936 consecutive patients who underwent DES implantation and did not experience ST during a follow-up of 12 months. Logistic regression analysis was conducted to determine the correlates of ST. Compared with patients without ST, patients with ST had a higher frequency of diabetes, acute postprocedural renal failure, and chronic renal failure. There were more bifurcation lesions, type C lesions, and a trend for smaller-diameter stents. Discontinuation of clopidogrel was higher in these patients (36.8% versus 10.7%; P < 0.0001). The mean duration to ST from the stent implantation was 8.9 +/- 8.5 days in subacute and 152.7 +/- 100.4 days in late thrombosis cases. Mortality was significantly higher in patients with ST compared with those without ST at 6 months (31% versus 3%; P < 0.001). Multivariate analysis detected cessation of clopidogrel therapy, renal failure, bifurcation lesions, and in-stent restenosis as significant correlates of ST ( P < 0.05). Conclusions - ST continues to be a serious complication of contemporary DES use. Careful management is warranted in patients with renal failure and in those undergoing treatment for in-stent restenosis and bifurcations. Special focus on clopidogrel compliance may minimize the incidence of ST after DES implantation.
引用
收藏
页码:1108 / 1113
页数:6
相关论文
共 50 条
  • [41] Mid- to long-term survival in patients with left ventricular dysfunction undergoing sirolimus- or paclitaxel-eluting stent implantation
    Nusca, Annunziata
    Lipinski, Michael J.
    Varma, Amit
    Appleton, Darryn L.
    Goudreau, Evelyne
    Cowley, Michael J.
    Wittkamp, Michael
    Di Sciascio, Germano
    Abbate, Antonio
    Vetrovec, George W.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2008, 51 (10) : B3 - B3
  • [42] Intravascular ultrasound findings in patients with restenosis of sirolimus- and paclitaxel-eluting stents
    Ohlmann, Patrick
    Mintz, Gary S.
    Kim, Sang-Wook
    Pichard, Augusto D.
    Satler, Lowel F.
    Kent, Kenneth M.
    Suddath, William O.
    Waksman, Ron
    Weissman, Nell J.
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2008, 125 (01) : 11 - 15
  • [43] Is sirolimus better for diabetics than paclitaxel? A contemporary comparative analysis of outcomes after sirolimus- and paclitaxel-eluting stent implantation
    Corbett, S
    Cosgrave, J
    Babic, R
    Melzi, G
    Aranzulla, T
    Morici, N
    Godino, C
    Chieffo, A
    Michev, I
    Airoldi, F
    Montorfano, M
    Carlino, M
    Sangiorgi, G
    Cololmbo, A
    HEART, 2006, 92 : A98 - A98
  • [44] Sirolimus- Versus Paclitaxel-Eluting Stents for the Treatment of Cardiac Allograft Vasculopathy
    Lee, Michael S.
    Tarantini, Giuseppe
    Xhaxho, Jola
    Yang, Tae
    Ehdaie, Ashkan
    Bhatia, Ravi
    Favaretto, Enrico
    Tobis, Jonathan
    JACC-CARDIOVASCULAR INTERVENTIONS, 2010, 3 (04) : 378 - 382
  • [45] Long term outcomes of paclitaxel-eluting stent implantation as an initial treatment strategy for sirolimus-eluting stent failure
    Levisay, Justin P.
    Price, Matthew J.
    Shaba, Wisam
    Stinis, Curtiss
    Valencia, Rafael
    Gollapudi, Raghu
    Schatz, Richard A.
    Teirstein, Paul S.
    CIRCULATION, 2007, 116 (16) : 468 - 469
  • [46] Comparable outcomes of sirolimus- and paclitaxel-eluting stents in diabetic patients undergoing percutaneous coronary intervention
    Chen, K. Y.
    Rha, S. W.
    Jin, Z.
    Minami, Y.
    Na, J. O.
    Choi, C. U.
    Suh, S. Y.
    Kim, J. W.
    Kim, E. J.
    Park, C. G.
    Oh, D. J.
    AMERICAN JOURNAL OF CARDIOLOGY, 2008, 101 (8B): : 47C - 48C
  • [47] Sirolimus-eluting stent is superior to paclitaxel-eluting stent for coronary intervention in patients with renal insufficiency: Long-term clinical outcomes
    Ann, Soe Hee
    Seo, Suk-Min
    Kim, Pum-Joon
    Koh, Yoon-Seok
    Her, Sung-Ho
    Shin, Dong Il
    Park, Hun-Jun
    Park, Chul Soo
    Lee, Jong Min
    Kim, Dong-Bin
    Chang, Kiyuk
    Chung, Wook-Sung
    Seung, Ki-Bae
    CARDIOLOGY JOURNAL, 2016, 23 (06) : 637 - 646
  • [48] The long-term safety of bare-metal, sirolimus- or paclitaxel-eluting stents for On-versus Off-label indications
    Daemen, J.
    Van Twisk, P. H.
    Van Domburg, R. T.
    Kukreja, N.
    Onuma, Y. N.
    Boersma, H.
    Serruys, P. W. J. C.
    EUROPEAN HEART JOURNAL, 2008, 29 : 516 - 516
  • [49] The long-term safety of bare-metal, sirolimus- or paclitaxel-eluting stents for on-versus off-label indications
    Daemen, Jaost
    van Twisk, Piet Hein
    van Domburg, Ron T.
    Boersma, Eric
    de Jaegere, Peter P. T.
    Serruys, Patrick W.
    AMERICAN JOURNAL OF CARDIOLOGY, 2007, 100 (8A): : 103L - 103L
  • [50] Long-Term TAXUS Paclitaxel-Eluting Stent Outcomes In the Elderly Patients
    Forman, Daniel E.
    Wei, Jeanne Y.
    Friedman, Mark I.
    Dawkins, Keith D.
    Baim, Donald S.
    CIRCULATION, 2008, 118 (18) : S1047 - S1047